The company said its product revenues rose during the fourth quarter thanks to an increase in T2Candida panel sales due to increased patient testing.
The infectious disease diagnostics firm secured eight new contracts covering 18 hospital in the US and Europe during the fourth quarter.
A hospital study demonstrated an average total cost saving of around $25,000 for each patient with candidemia.
The new women's health and STI tests for the BD Max platform are part of a small, focused panel approach which the firm believes will resonate with physicians and labs.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The AmpiProbe Candidiasis test identifies five common species of Candida bacteria from a vaginal swab, and is the third test from Enzo to be approved in NY state.
The PCR-based panel tests for the pathogens that cause three types of gynecological infection: bacterial vaginosis, candidiasis, and trichomoniasis.
The Scottish firm's product pipeline includes an identification test for bacterial gastroenteritis and genes for Carbapenem resistance.
The British firm is launching its RenDx system and Fungiplex PCR-based assay for Candida and Aspergillus fungal infections.
The company also posted increased operating expenses related to R&D efforts and the added cost of doing business as a public company.
The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.
Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.
In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.
China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.